MDV3100 (Enzalutamide) is a potent androgen receptor antagonist. It affects AR, MAPK, and mTOR signaling pathways, by blocking AR nuclear translocation and transcriptional activity, thereby inhibiting prostate cancer cell proliferation and promoting apoptosis.
MDV3100 (Enzalutamide) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for MDV3100 (Enzalutamide) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.